Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -37,645 | -19,482 | -8,522 | -6,561 | 1,052 |
| Depreciation Amortization | 454 | 605 | 628 | 546 | 631 |
| Accounts payable and accrued liabilities | -701 | 800 | 519 | 242 | 134 |
| Other Working Capital | -469 | -762 | 647 | 94 | 296 |
| Other Operating Activity | 24,409 | 6,095 | 254 | -375 | -8,140 |
| Operating Cash Flow | $-13,952 | $-12,744 | $-6,475 | $-6,054 | $-6,028 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 5,520 | -28 | -91 | -7 | N/A |
| Net Acquisitions | N/A | -67 | N/A | N/A | N/A |
| Other Investing Activity | 1,077 | 5,309 | 0 | 0 | 0 |
| Investing Cash Flow | $6,597 | $5,214 | $-91 | $-7 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 4,974 | N/A | N/A | 450 | 3,991 |
| Debt Issued | N/A | N/A | N/A | 117 | N/A |
| Debt Repayment | -259 | -276 | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | 13,068 | 6,134 | 5,999 |
| Other Financing Activity | 11,729 | 67 | 12 | 0 | -3,986 |
| Financing Cash Flow | $16,443 | $-209 | $13,079 | $6,701 | $6,005 |
| Beginning Cash Position | 1,249 | 8,988 | 2,474 | 1,835 | 1,858 |
| End Cash Position | 10,337 | 1,249 | 8,988 | 2,474 | 1,835 |
| Net Cash Flow | $9,088 | $-7,739 | $6,514 | $640 | $-23 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,952 | -12,744 | -6,475 | -6,054 | -6,028 |
| Capital Expenditure | -13 | -28 | -91 | -7 | N/A |
| Free Cash Flow | -13,965 | -12,772 | -6,566 | -6,061 | -6,028 |